Home/Investors/EQT Life Sciences

EQT Life Sciences

Biotech Investor · 3 portfolio companies

Portfolio

3

Combined Value

$554.0M

Focus Areas

5

Top Stage

Phase 1

Investment Focus

Fibrosis Immunology & Inflammatory Diseases Neurodegenerative Diseases Ophthalmology Genetic Diseases

Portfolio Companies

Company	Stage	Valuation	Focus
Agomab Therapeutics	Phase 1	$554.0M	Fibrosis, Immunology & Inflammatory Diseases
AviadoBio	Phase 1	—	Neurodegenerative Diseases, Ophthalmology
SpliceBio	Phase 1	—	Ophthalmology, Genetic Diseases

Frequent Co-Investors

LifeArc Ventures1 shared Johnson & Johnson Innovation – JJDC1 shared Ysios Capital1 shared F-Prime Capital1 shared Sanofi Ventures1 shared New Enterprise Associates1 shared New Enterprise Associates (NEA)1 shared Novartis Venture Fund1 shared